All > Meningioma

Lutathera for Meningioma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
MeningiomaLutathera - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether Lutathera is effective in treating meningioma. Lutathera will be given intravenously every 8 weeks for 4 doses, and PET-MRI scans will be done before treatment and 6 months after the start of treatment.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Talk STEM Familia Treatment Condition
1
REC-2282
1
25 Gy in 5 fractions

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 2 Years Post Treatment

12 months
Objective Response Rate (ORR)
Overall Survival at 12 months (OS-12)
2 Years Post Treatment
Overall Survival (OS)
Progression Free Survival (PFS)
6 Months
Progression Free Survival at 6 months (PFS-6)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Talk STEM Familia Treatment Condition
2
REC-2282
1
25 Gy in 5 fractions

Trial Design

1 Treatment Group

Lutathera
1 of 1

Experimental Treatment

32 Total Participants · 1 Treatment Group

Primary Treatment: Lutathera · No Placebo Group · Phase 2

Lutathera
Drug
Experimental Group · 1 Intervention: Lutathera · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years post treatment

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,264 Previous Clinical Trials
753,559 Total Patients Enrolled
1 Trials studying Meningioma
5 Patients Enrolled for Meningioma
Erik Sulman, MDPrincipal InvestigatorNew York Langone Health
1 Previous Clinical Trials
10 Total Patients Enrolled
Sylvia Kurz, MDPrincipal InvestigatorNYU Langone Health
2 Previous Clinical Trials
16 Total Patients Enrolled
Erik Sukman, MDPrincipal InvestigatorNew York Langone Health

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a measurable disease defined as at least one lesion measuring ≥10 mm in at least one dimension by contrast-enhanced MRI performed within 30 days prior to study registration.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top